Common Use of Letrozole (Femara)
Letrozole is primarily used for the treatment of hormone receptor-positive breast cancer in postmenopausal women, both as adjuvant therapy after initial treatment and as extended adjuvant therapy following 5 years of tamoxifen. 1
Primary Indications
Breast Cancer Treatment
Letrozole functions as a third-generation aromatase inhibitor that blocks estrogen synthesis by inhibiting the final step of the estrogen biosynthetic pathway 2, 3. The drug is indicated for:
- Adjuvant therapy in postmenopausal women with stage I-III hormone receptor-positive breast cancer
- Extended adjuvant therapy after completion of 5 years of tamoxifen treatment
- First-line treatment for advanced or metastatic hormone-responsive breast cancer
- Second-line treatment after disease progression on antiestrogen therapy
The standard dose is 2.5 mg daily administered orally 1.
Clinical Trial Evidence
Multiple large phase III trials support letrozole's efficacy 1:
- MA.17R trial: Compared letrozole 2.5 mg daily versus placebo for 5 years in 1,918 women who had already received 4.5-6 years of aromatase inhibitor therapy
- NSABP B-42 study: Evaluated letrozole versus placebo in 3,923 women who completed 5 years of endocrine therapy
- BIG 1-98 trial: Demonstrated a 19% reduction in disease-free survival events with letrozole compared to tamoxifen 4
Emerging Uses in Reproductive Medicine
Beyond oncology, letrozole has gained recognition for ovulation induction in women with polycystic ovary syndrome (PCOS) and infertility 5, 6, 7. It is increasingly recommended as a first-line agent for ovulation induction due to better pregnancy and live birth rates compared to clomiphene citrate, particularly in women with clomiphene resistance 7.
Additional reproductive applications include:
- In vitro fertilization (IVF) protocols
- In vitro maturation (IVM)
- Management of ovarian hyperstimulation syndrome risk
- Experimental use in ectopic pregnancy management 8, 9
Key Clinical Advantages
Letrozole demonstrates superior efficacy to tamoxifen in multiple settings 2, 10:
- Longer time to disease progression (9.4 vs 6.0 months, p < 0.0001) in advanced breast cancer
- 43% relative reduction in disease recurrences when used as extended adjuvant therapy
- Better neoadjuvant response rates compared to tamoxifen
The drug is generally well tolerated with a favorable safety profile similar to tamoxifen 2, 10. Common adverse events include hot flushes, arthralgia, myalgia, and arthritis 1. However, extended use is associated with increased risk of bone fractures (OR 1.34, NNH 72) and cardiovascular events (OR 1.18, NNH 122) 1.
Important Caveats
- Long-term effects on bone mineral density require monitoring during extended therapy
- Not indicated for premenopausal women in breast cancer treatment (requires postmenopausal status)
- The drug maintains quality of life without significant deterioration compared to placebo 11
- Cost-effectiveness analyses support its use as first-line therapy over tamoxifen from multiple healthcare system perspectives 3